Aarti Pharmalabs Limited announced the outcome of its Board of Directors meeting held on August 7, 2026. The Board approved the unaudited financial results for the quarter ended June 30, 2026, alongside a capacity addition for a development of intermediate block at an estimated capex of ₹149 Crores. Key leadership changes were also approved, including a new Managing Director effective October 1, 2026.
Board Meeting Highlights Key Decisions
The Board of Directors of Aarti Pharmalabs Limited convened on Friday, August 7, 2026, to discuss and approve several crucial company matters. The meeting’s outcomes are significant for stakeholders, detailing financial performance, strategic growth initiatives, and leadership transitions.
Financial Results and Limited Review
The Board considered and approved the unaudited financial results for the quarter ended June 30, 2026. These results, presented on a standalone and consolidated basis, were accompanied by a Limited Review Report from the Audit Committee. The standalone financial results for the quarter ended June 30, 2026, show a Profit After Tax of ₹7,130.66 Lakhs, with a total comprehensive income of ₹7,312.80 Lakhs.
Capacity Expansion and Capex
A significant strategic decision was the approval of an approved capacity addition for the development of an intermediate block. This expansion is projected to incur an estimated capital expenditure (capex) of ₹149 Crores. The expansion is aimed at serving intermediate and CDMO customers, with the period for addition estimated at 1 year. Financing will be sourced through internal accruals and borrowings.
Leadership Transitions Approved
In a notable governance update, the Board approved changes in key leadership designations, effective October 1, 2026, subject to shareholder approval:
- Shri Rashesh C. Gogri (DIN: 00066291) will transition from Non-Executive Director to Managing Director.
- Smt. Hetal Gogri Gala (DIN: 00005499) will move from Managing Director to Executive Director.
These appointments are based on the recommendations of the Nomination and Remuneration Committee.
Committee Reconstitutions
Furthermore, the Board approved the reconstitution of its key committees:
- Audit Committee members were confirmed, with Shri Bhavesh Vora appointed as Chairman.
- The Corporate Social Responsibility (CSR) Committee was reconstituted, naming Smt. Hetal Gogri Gala as Chairperson.
- The Stakeholders Relationship Committee was also reconstituted, with Shri Parimal Desai as Chairman.
These reconstitutions are effective from October 1, 2026, for the Audit and CSR committees, and with immediate effect for the Stakeholders Relationship Committee.
Source: BSE
